1,208 results match your criteria Prostate Cancer - Management of Localized Disease


Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.

Prostate Cancer Prostatic Dis 2021 Jun 9. Epub 2021 Jun 9.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Background: The appropriate management of localized or metastatic hormone-sensitive prostate cancer (HSPC) patients harboring tumor BRCA mutations (tBRCAm) is not well-characterized. We sought to evaluate the prevalence and clinical outcomes of patients with tBRCAm and localized or de novo metastatic HSPC.

Methods: We performed a multicenter, international, retrospective cohort study of localized (cohort 1) and de novo metastatic (cohort 2) HSPC patients who underwent tumor BRCA1 and BRCA2 sequencing from 2013 to 2019. Read More

View Article and Full-Text PDF

aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.

J Nucl Med 2021 May 28. Epub 2021 May 28.

Ronald Reagan UCLA Medical Center, United States.

Standardized staging and quantitative reporting is necessary to demonstrate the association of F-DCFPyL PET/CT (PSMA) imaging with clinical outcome. This work introduces an automated platform to implement and extend the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria - aPROMISE. The objective is to validate the performance of aPROMISE in staging and quantifying disease burden in patients with prostate cancer who undergo PSMA Imaging. Read More

View Article and Full-Text PDF

[Practical recommendations for the management of testosterone deficiency].

Prog Urol 2021 Jun-Jul;31(8-9):458-476. Epub 2021 May 24.

Médecine de la reproduction, CHU de Toulouse, site de Paule-de-Viguier, Toulouse, France; Département d'urologie, transplantation rénale et andrologie, hôpital Rangueil, CHU de Toulouse, France. Electronic address:

Objectives: The Francophone Society of Sexual Medicine (SFMS) and the Andrology and Sexual Medicine Committee (CAMS) of the French Association of Urology (AFU) have brought together a panel of experts to develop French recommendations for the management of testosterone deficiency (TD).

Methods: Systematic review of the literature between 01/2000 and 07/2019. Use of the method of recommendations for clinical practice (RPC) and the AGREE II grid. Read More

View Article and Full-Text PDF

Available evidence on HIFU for focal treatment of prostate cancer: a systematic review.

Int Braz J Urol 2021 Apr 20;47. Epub 2021 Apr 20.

Department of Urology, Institut Mutualiste Montsouris, Paris, France.

Purpose: Prostate cancer (PCa) is the second most common oncologic disease among men. Radical treatment with curative intent provides good oncological results for PCa survivors, although definitive therapy is associated with significant number of serious side-effects. In modern-era of medicine tissue-sparing techniques, such as focal HIFU, have been proposed for PCa patients in order to provide cancer control equivalent to the standard-of-care procedures while reducing morbidities and complications. Read More

View Article and Full-Text PDF

Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.

Radiother Oncol 2021 May 5;160:115-119. Epub 2021 May 5.

Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Background/objective: The optimal prognostic value of testosterone following androgen deprivation therapy (ADT) is controversial. We studied the effect of serum testosterone levels on clinical outcome in localized prostate cancer (PCa) treated with ADT and high-dose radiotherapy (HRT).

Patients And Methods: The DART01/05 trial randomized 355 men with intermediate and high-risk PCa to 4 months of ADT plus HRT (STADT, N = 178) or the same treatment followed by 24 months of ADT (LTADT, N = 177). Read More

View Article and Full-Text PDF

Functional and Patient Reported Outcomes Following Total Glans Resurfacing.

J Sex Med 2021 Apr 29. Epub 2021 Apr 29.

Urology Clinic - A.O.U. "Città della Salute e della Scienza" - Molinette Hospital, University of Turin, Italy.

Background: Whilst there is a trend away from aggressive nonorgan sparing surgical treatments for malignant penile disease, a variety of penile preservation options exist but functional outcomes and patient reported outcomes (PROs) in this area are poorly reported to date.

Aim: The aim of this study is to report functional outcomes and PROs of total glans resurfacing (TGR) in a consecutive series of patients with lichen sclerosis (LS) or localized penile cancer (PC).

Methods: From 2004 to 2018 a consecutive series of patients underwent TGR for the management of LS or localized PC in a tertiary referral network. Read More

View Article and Full-Text PDF

Prostate cancer management in the era of COVID-19: Recommendations from the Hong Kong Urological Association and Hong Kong Society of Uro-oncology.

Asia Pac J Clin Oncol 2021 Apr;17 Suppl 3:48-54

Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Hong Kong.

Aim: In response to the fast-developing coronavirus disease 2019 (COVID-19) pandemic, special arrangement and coordination are urgently required in the interdisciplinary care of patients across different medical specialties. This article provides recommendations on the management of different stages of localized or metastatic prostate cancer (PC) amid this pandemic.

Methods: The Hong Kong Urological Association and Hong Kong Society of Uro-oncology formed a joint discussion panel, which consisted of six urologists and six clinical oncologists with extensive experience in the public and private sectors. Read More

View Article and Full-Text PDF

Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

JCO Glob Oncol 2021 Apr;7:523-529

A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil.

Purpose: A group of international urology and medical oncology experts developed and completed a survey on prostate cancer (PCa) in developing countries. The results are reviewed and summarized, and recommendations on consensus statements for very low-, low-, and intermediate-risk PCa focused on developing countries were developed.

Methods: A panel of experts developed more than 300 survey questions of which 66 questions concern the principal areas of interest of this paper: very low, low, and intermediate risk of PCa in developing countries. Read More

View Article and Full-Text PDF

Optimizing the diagnosis and management of ductal prostate cancer.

Nat Rev Urol 2021 Jun 6;18(6):337-358. Epub 2021 Apr 6.

Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Ductal adenocarcinoma (DAC) is the most common variant histological subtype of prostate carcinoma and has an aggressive clinical course. DAC is usually characterized and treated as high-risk prostatic acinar adenocarcinoma (PAC). However, DAC has a different biology to that of acinar disease, which often poses a challenge for both diagnosis and management. Read More

View Article and Full-Text PDF

Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.

Eur Urol 2021 Mar 27. Epub 2021 Mar 27.

Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, MD, USA. Electronic address:

Background: Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) have shown lower rates of recurrence among patients with minimal residual disease after treatment. The molecular features that distinguish exceptional responders from poor responders are not known. Read More

View Article and Full-Text PDF

Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes.

World J Urol 2021 Mar 2. Epub 2021 Mar 2.

Department of Urology, University of Michigan Health System, University of Michigan, 1500 E Medical Center Drive, 7308 CCC, Ann Arbor, MI, 48109, USA.

Introduction: Active surveillance (AS) has been widely adopted for the management of men with low-risk prostate cancer. However, there is still a lack of consensus surrounding the optimal approach for monitoring men in AS protocols. While conservative management aims to reduce the burden of invasive testing without compromising oncological safety, inadequate assessment can result in misclassification and unintended over- or undertreatment, leading to increased patient morbidity, cost, and undue risk. Read More

View Article and Full-Text PDF

Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.

Prostate Cancer Prostatic Dis 2021 Feb 8. Epub 2021 Feb 8.

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Background: Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. Read More

View Article and Full-Text PDF
February 2021

Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report.

Urology 2021 Feb 6. Epub 2021 Feb 6.

Department of Urology, Glickman Urologic and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.

The Breast Cancer Gene (BRCA) confers an 8.6-fold higher risk of developing prostate cancer in men ≤ 65 years of age and portends a worse prognosis as compared to noncarriers even in patients with low volume, localized disease. The BRCA2 gene, in particular, imparts a more biologically aggressive form of prostate cancer and a higher prostate cancer specific mortality. Read More

View Article and Full-Text PDF
February 2021

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.

J Natl Compr Canc Netw 2021 02 2;19(2):134-143. Epub 2021 Feb 2.

Huntsman Cancer Institute at the University of Utah; and.

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. Read More

View Article and Full-Text PDF
February 2021

Prostate cancer.

Nat Rev Dis Primers 2021 02 4;7(1). Epub 2021 Feb 4.

Cancer Research UK Manchester Institute, University of Manchester, Manchester Cancer Research Centre, Manchester, UK.

Prostate cancer is a complex disease that affects millions of men globally, predominantly in high human development index regions. Patients with localized disease at a low to intermediate risk of recurrence generally have a favourable outcome of 99% overall survival for 10 years if the disease is detected and treated at an early stage. Key genetic alterations include fusions of TMPRSS2 with ETS family genes, amplification of the MYC oncogene, deletion and/or mutation of PTEN and TP53 and, in advanced disease, amplification and/or mutation of the androgen receptor (AR). Read More

View Article and Full-Text PDF
February 2021

Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.

Biomed Res Int 2021 13;2021:6641429. Epub 2021 Jan 13.

Department of Genetics and the Bioinformatics and Genomics Program, Louisiana State University Health Sciences Center, School of Medicine, 533 Bolivar Street, New Orleans, LA 70112-1393, USA.

Background: Majority of prostate cancer (PCa) deaths are attributed to localized high-grade aggressive tumours which progress rapidly to metastatic disease. A critical unmet need in clinical management of PCa is discovery and characterization of the molecular drivers of aggressive tumours. The development and progression of aggressive PCa involve genetic and epigenetic alterations occurring in the germline, somatic (tumour), and epigenomes. Read More

View Article and Full-Text PDF

Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer.

J Urol 2021 Apr 1;205(4):1047-1054. Epub 2020 Dec 1.

Genomic Health Inc., an Exact Sciences corporation, Redwood City, California.

Purpose: Adoption of prognostic molecular assays for prostate cancer requires evidence of robust performance in different racial groups. Retrospective analysis was conducted to assess the performance of the Oncotype DX Genomic Prostate Score test in African American and Caucasian American men with surgically treated prostate cancer.

Materials And Methods: We compared the assay results (scale 0-100) and the 4 gene group scores in biopsy specimens from 201 African American and 1,144 Caucasian American men with clinically localized prostate cancer in 6 cohorts. Read More

View Article and Full-Text PDF

Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide.

Expert Rev Anticancer Ther 2021 Feb 8:1-15. Epub 2021 Feb 8.

Department of Radiation Oncology, London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.

Introduction: PSMA-targeted PET/CT is a 'Next Generation Imaging' technique with superior sensitivity and specificity for detecting recurrent prostate cancer compared with conventional imaging, allowing more accurate staging and re-staging.

Areas Covered: This article reviews the role of PSMA-targeted PET/CT in clinical management of men with recurrent prostate cancer.

Expert Opinion: Through enhanced spatial characterization of recurrent prostate cancer, PSMA-targeted PET/CT has shown significant impact on management decisions. Read More

View Article and Full-Text PDF
February 2021

Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies.

JNCI Cancer Spectr 2020 Dec 11;4(6):pkaa081. Epub 2020 Sep 11.

Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA.

Background: Given similarities in the mediators of medication allergy (MA) and tissue response to radiotherapy, we assessed whether outcomes following prostate radiotherapy differ in patients with MAs.

Methods: A total 587 men with known MA history and nonmetastatic prostate cancer underwent radiotherapy from 1989 to 2006. Clinicopathologic and treatment variables were analyzed for association with freedom from biochemical failure (FFBF) and late treatment-related, physician-defined Radiation Therapy Oncology Group gastrointestinal (GI) and genitourinary (GU) toxicity. Read More

View Article and Full-Text PDF
December 2020

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.

Eur Urol Oncol 2021 Feb 31;4(1):1-9. Epub 2020 Dec 31.

Cancer Risk Assessment and Clinical Cancer Genetics, Departments of Medical Oncology, Cancer Biology, and Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address:

Context: Germline testing (GT) is increasingly impacting prostate cancer (PCa) management and screening, with direct effects in urology, medical oncology, and radiation oncology. The majority of testing indications and recommendations center on men with metastatic disease, although guidelines now encompass newly diagnosed, early-stage PCa and entail assessment of personal history, pathologic features, and family history to determine eligibility for testing.

Objective: To describe current guidelines on GT for men with PCa and the impact on management. Read More

View Article and Full-Text PDF
February 2021

Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials.

World J Urol 2021 Mar 2;39(3):729-739. Epub 2021 Jan 2.

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. Read More

View Article and Full-Text PDF

Identifying Risk Profiles of Malignant Prostate Cancer Surgical Delay Using a Person-Centered Approach to Understand Prostate Cancer Disparities: The Constellation of Health Determinants Using Latent Class Analysis on Cancer Registry Data.

Am J Mens Health 2020 Nov-Dec;14(6):1557988320984282

Division of Intramural Research, National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, MD, USA.

Surgical prostate cancer (PCa) treatment delay (TD) may increase the likelihood of recurrence of disease, and influence quality of life as well as survival disparities between Black and White men. We used latent class analysis (LCA) to identify risk profiles in localized, malignant PCa surgical treatment delays while assessing co-occurring social determinants of health. Profiles were identified by age, marital status, race, county of residence (non-Appalachian or Appalachian), and health insurance type (none/self-pay, public, or private) reported in the Tennessee Department of Health cancer registry from 2005 to 2015 for adults ≥18 years ( = 18,088). Read More

View Article and Full-Text PDF
December 2020

Pathology grade influences competing mortality risks in elderly men with prostate cancer.

Urol Oncol 2020 Dec 19. Epub 2020 Dec 19.

Department of Urology, University of Florida, Jacksonville, FL.

Background: Recent guidelines recommend active management of prostate cancer (CaP), especially high-risk disease, in elderly men. However, descriptive data from a large cohort with extended follow up on the risk of death from CaP in men diagnosed over 70 years of age and its relationship to Gleason score (GS) and serum prostate specific antigen (PSA) level is lacking. Using the Surveillance, Epidemiology, and End Results database, we evaluated the influence of GS and serum PSA levels on the risks of mortality from PC (PCM) and mortality from other causes in localized (LPC) and metastatic (MPC) disease in elderly population. Read More

View Article and Full-Text PDF
December 2020

Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.

Urol Oncol 2020 Dec 8. Epub 2020 Dec 8.

Department of Health Policy and Management, Emory University, Atlanta, GA. Electronic address:

Background: The treatment for men diagnosed with localized prostate cancer has changed over time given the increased attention to the harms associated with over-diagnosis and the development of protocols for active surveillance.

Methods: We examined trends in the treatment of men diagnosed with localized prostate cancer between 2004 and 2015, using the most recently available data from Surveillance, Epidemiology, and End Results Program (SEER)-Medicare. Patients were stratified by Gleason score, age, and race groups. Read More

View Article and Full-Text PDF
December 2020

A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.

Eur Urol 2021 Mar 5;79(3):374-383. Epub 2020 Dec 5.

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address:

Context: Molecular biomarkers aim to address the established limitations of clinicopathologic factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to whether sufficient evidence supports adoption of these biomarkers for clinical use.

Objective: To perform a systematic review of the available evidence supporting the clinical utility of the Decipher genomic classifier (GC). Read More

View Article and Full-Text PDF

Surgical Delay and Pathological Outcomes for Clinically Localized High-Risk Prostate Cancer.

JAMA Netw Open 2020 12 1;3(12):e2028320. Epub 2020 Dec 1.

Division of Urology, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia.

Importance: There is a lack of data evaluating the association of surgical delay time (SDT) with outcomes in patients with localized, high-risk prostate cancer.

Objective: To investigate the association of SDT of radical prostatectomy and final pathological and survival outcomes.

Design, Setting, And Participants: This cohort study used data from the US National Cancer Database (NCDB) and identified all patients with clinically localized (cT1-2cN0cM0) high-risk prostate adenocarcinoma diagnosed between 2006 and 2016 who underwent radical prostatectomy. Read More

View Article and Full-Text PDF
December 2020

Psychological nursing intervention on anxiety and depression in patients with urinary incontinence after radical prostatectomy: A randomized controlled study protocol.

Medicine (Baltimore) 2020 Nov;99(48):e23127

Department of Traditional Chinese Medicine, First People's Hospital of Chenzhou City, Hunan Province, China.

Background: Prostate cancer (PC) is one of the most familiar disease of the male reproductive system globally. In treating the clinically localized PC, the radical prostatectomy is regarded as a gold standard, but it is associated with syndromes as urinary incontinence (UI), which can have a significant impact on patients' quality of life. Nurse takes responsibility in the management of the UI for their convenience compared with doctors to contact with patients and build better trust relationships with survivals. Read More

View Article and Full-Text PDF
November 2020

Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings.

J Urol 2021 04 18;205(4):1055-1062. Epub 2020 Nov 18.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.

Purpose: We investigated whether T2-weighted magnetic resonance imaging findings could improve upon established prognostic indicators of metastatic disease and prostate cancer specific survival.

Materials And Methods: For a cohort of 3,406 consecutive men who underwent prostate magnetic resonance imaging before prostatectomy (2,160) or radiotherapy (1,246) between 2001 and 2006, T2-weighted magnetic resonance imaging exams were retrospectively interpreted and categorized as I) no focal suspicious lesion, II) organ confined focal lesion, III) focal lesion with extraprostatic extension or IV) focal lesion with seminal vesicle invasion. Clinical risk was recorded based on European Association of Urology (EAU) guidelines and the Cancer of the Prostate Risk Assessment (CAPRA) scoring system. Read More

View Article and Full-Text PDF

The role of multiparametric magnetic resonance imaging in the selection and follow-up of patients undergoing active surveillance for prostate cancer. An European Section of Uro-Technology (ESUT) review.

Actas Urol Esp (Engl Ed) 2021 Apr 11;45(3):188-197. Epub 2020 Nov 11.

Departamento de Urología, Institut Mutualiste Montsouris, París, Francia.

Introduction: In recent years, active surveillance (AS) has gained popularity as a safe and reasonable option for patients with low-risk, clinically localized prostate cancer.

Objective: To summarize the latest information regarding the use of mpMRI in the setting of active surveillance (AS) for the management of prostate cancer (PCa).

Evidence Acquisition: A PubMed-based, English literature search was conducted through February 2020. Read More

View Article and Full-Text PDF

Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.

Int J Radiat Oncol Biol Phys 2021 Jul 10;110(3):700-707. Epub 2020 Nov 10.

Cedars-Sinai Medical Center.

Purpose: To report the long-term outcome of patients with prostate cancer treated with external beam radiation therapy and high dose rate (HDR) brachytherapy from a prospective multi-institutional trial conducted by NRG Oncology/RTOG.

Methods And Materials: Patients with clinically localized (T1c-T3b) prostate cancer without prior history of transurethral resection of prostate or hip prosthesis were eligible for this study. All patients were treated with a combination of 45 Gy in 25 fractions from external beam radiation therapy and one HDR implant delivering 19 Gy in 2 fractions. Read More

View Article and Full-Text PDF